New NF2 Avastin Trial to Open at Johns Hopkins, MGH and NIH

• Phase 2 Study of Bevacizumab (Avastin) in Children and Adults With Neurofibromatosis Type 2 and Symptomatic Vestibular Schwannoma. ClinicalTrials.gov Identifier: NCT01207687

A clinical trial for people with NF2 using bevacizumab (Avastin) to possibly improve hearing and decrease the size of vestibular tumors is being opened on October 18, 2010.

This study is a collaboration between Johns Hopkins Hospital (serving as the primary coordinating site), Massachusetts General Hospital and the National Cancer Institute. People with NF2 who are 12 years of age or older and who have recently experiences hearing loss due to their vestibular tumors may be eligible for this study. People with NF2 who have worsening hearing in their only hearing ear are considered particularly appropriate study candidates.

The present trial seeks to assess the efficacy of bevacizumab in patients ranging in age from 12 years old and older. Adult and pediatric patients (12 years and older) with NF2 and symptomatic VSs will be eligible. Bevacizumab will be administered every three weeks for 48 weeks and response will be evaluated. Detailed safety and tolerability data will be collected. This work will be carried out at Johns Hopkins (coordinating center), the Massachusetts General Hospital and the NCI Pediatric Oncology Branch.

If you are interested in participating in this study or learning more about it, please contact Amanda Bergner in the Central Study Office at Johns Hopkins at 410-502-6732, or email at : abergne1@jhmi.edu.